Abstract
Rheumatoid arthritis (RA) patients have increased risk of cardiovascular disease (CVD) death. Elevated asymmetric dimethylarginine (ADMA) levels have been reported to be an independent predictor of CVD morbidity and mortality, however, the role of ADMA in RA remains undetermined. To derive a more accurate estimation on circulating ADMA levels in RA patients, a meta-analysis was performed. Embase, PubMed, and The Cochrane Library database (up to October 7 2018) were used to acquire published literatures. Heterogeneity test was performed by the Q statistic and quantified using I2. Publication bias was evaluated using a funnel plot and Egger’s linear regression test. A total of 174 articles were identified, 16 studies with 1365 subjects (666 RA patients and 699 healthy individuals) were ultimately included. Plasma/serum ADMA levels appeared to be higher in RA patients than healthy controls (SMD = 0.84, 95% CI 0.32, 1.35). By assessing the BMI, age, disease duration and disease activity as subgroups, BMI ≥ 24 and BMI < 24 groups both showed elevated ADMA levels than controls, disease duration ≥ 8, age < 50 and disease activity ≥ 3.2 and < 5.1 group had a higher ADMA level than control groups. However, disease duration < 8, disease activity ≥ 5.1 and age ≥ 50 groups showed no difference between two groups. Circulating ADMA levels are higher in RA patients compared with healthy controls. In addition, ADMA levels are influenced by age, disease duration and disease activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akgol G, Gulkesen A, Telo S, Ulusoy H, Poyraz AK, Alkan G, Kaya A (2016) Can serum asymmetric dimethyl-arginine and homocysteine levels be a new activity parameter of disease in patients with rheumatoid arthritis? Int J Clin Exp Med 9:14586–14595
Antoniades C et al (2011) Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 58:93–98. https://doi.org/10.1161/HYPERTENSIONAHA.110.168245
Atzeni F, Sarzi-Puttini P, De Blasio G, Delfino L, Tomasoni L, Turiel M (2007) Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. Ann N Y Acad Sci 1108:392–397
Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59:1690–1697. https://doi.org/10.1002/art.24092
Bedford MT, Clarke SG (2009) Protein arginine methylation in mammals: who, what, and why. Mol Cell 33:1–13. https://doi.org/10.1016/j.molcel.2008.12.013
Boger RH et al (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87:99–105
Boger RH et al (2009) Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119:1592–1600. https://doi.org/10.1161/CIRCULATIONAHA.108.838268
Chandrasekharan UM, Wang Z, Wu Y, Wilson Tang WH, Hazen SL, Wang S, Elaine Husni M (2018) Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. Arthritis Res Ther 20:123. https://doi.org/10.1186/s13075-018-1616-x
Di Franco M et al (2012) Serum levels of asymmetric dimethylarginine and apelin as potential markers of vascular endothelial dysfunction in early rheumatoid arthritis. Mediators Inflamm 2012:347268. https://doi.org/10.1155/2012/347268
Di Franco M, Lucchino B, Conti F, Valesini G, Spinelli FR (2018) Asymmetric dimethyl arginine as a biomarker of atherosclerosis in rheumatoid arthritis. Mediators Inflamm 2018:3897295. https://doi.org/10.1155/2018/3897295
Dimitroulas T, Sandoo A, Kitas GD (2012) Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int J Mol Sci 13:12315–12335. https://doi.org/10.3390/ijms131012315
Dimitroulas T, Sandoo A, Hodson J, Smith J, Panoulas VF, Kitas GD (2014) Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. Atherosclerosis 237:38–44. https://doi.org/10.1016/j.atherosclerosis.2014.07.033
Dimitroulas T, Hodson J, Panoulas VF, Sandoo A, Smith J, Kitas G (2017a) Genetic variations in the alanine-glyoxylate aminotransferase 2 (AGXT2) gene and dimethylarginines levels in rheumatoid arthritis. Amino Acids 49:1133–1141. https://doi.org/10.1007/s00726-017-2413-6
Dimitroulas T, Hodson J, Sandoo A, Smith J, Kitas GD (2017b) Endothelial injury in rheumatoid arthritis: a crosstalk between dimethylarginines and systemic inflammation. Arthritis Res Ther 19:32. https://doi.org/10.1186/s13075-017-1232-1
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Erre GL et al (2016) Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: a case-control study. J Int Med Res 44:76–80. https://doi.org/10.1177/0300060515593255
Fiskerstrand T, Ueland PM, Refsum H (1997) Folate depletion induced by methotrexate affects methionine synthase activity and its susceptibility to inactivation by nitrous oxide. J Pharmacol Exp Ther 282:1305–1311
Halcox JP et al (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106:653–658
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. https://doi.org/10.1002/sim.1186
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092–3095
Karaoğlan Belgin ÖG, Özdoğan V, Cumaoğlu A, Oktar S, Tas N, Aricioglu A (2011) Investigation of the correlation between ADMA levels and carotid artery intima-media thickness in rheumatoid arthritis patients. Turk J Phys Med Rehab 57:114–118. https://doi.org/10.4274/tftr.27879
Klimek E et al (2014) Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm 2014:681635. https://doi.org/10.1155/2014/681635
Korkosz M et al (2013) Disparate effects of anti-TNF-alpha therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis. Pharmacol Rep 65:891–897
Kubes P, Suzuki M, Granger DN (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 88:4651–4655
Kwasny-Krochin B, Gluszko P, Undas A (2012) Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation. Pol Arch Med Wewn 122:270–276
Lambden S et al (2016) Hypoxia causes increased monocyte nitric oxide synthesis which is mediated by changes in dimethylarginine dimethylaminohydrolase 2 expression in animal and human models of normobaric hypoxia Nitric oxide. Biol Chem 58:59–66. https://doi.org/10.1016/j.niox.2016.06.003
Leiper J, Murray-Rust J, McDonald N, Vallance P (2002) S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 99:13527–13532. https://doi.org/10.1073/pnas.212269799
Liu X et al (2016) Effect of asymmetric dimethylarginine (ADMA) on heart failure development nitric oxide. Biol Chem 54:73–81. https://doi.org/10.1016/j.niox.2016.02.006
Liu X, Xu X, Shang R, Chen Y (2018) Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease Nitric oxide. Biol Chem 78:113–120. https://doi.org/10.1016/j.niox.2018.06.004
Middleton J, Americh L, Gayon R, Julien D, Aguilar L, Amalric F, Girard JP (2004) Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky. Arthritis Res Ther 6:60–72. https://doi.org/10.1186/ar1156
Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA (2003) Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation 108:1493–1498. https://doi.org/10.1161/01.CIR.0000089087.25930.FF
Radhakutty A et al (2017) Opposing effects of rheumatoid arthritis and low dose prednisolone on arginine metabolomics. Atherosclerosis 266:190–195. https://doi.org/10.1016/j.atherosclerosis.2017.10.004
Rudan I et al (2015) Prevalence of rheumatoid arthritis in low- and middle-income countries: a systematic review and analysis. J Global Health 5:010409. https://doi.org/10.7189/jogh.05.010409
Sandoo A, Dimitroulas T, Toms TE, Hodson J (2012a) Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis. Clin Biochem 45:1399–1403. https://doi.org/10.1016/j.clinbiochem.2012.07.092
Sandoo A et al (2012b) Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis. Clin Exp Rheumatol 30:388–396
Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD (2015) Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology 54:1145–1152. https://doi.org/10.1093/rheumatology/keu349
Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108:2957–2963. https://doi.org/10.1161/01.cir.0000099844.31524.05
Schlesinger S, Sonntag SR, Lieb W, Maas R (2016) Asymmetric and symmetric dimethylarginine as risk markers for total mortality and cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. PLoS One 11:e0165811. https://doi.org/10.1371/journal.pone.0165811
Senturk T, Yilmaz N, Sargin G, Koseoglu K, Yenisey C (2016) Relationship between asymmetric dimethylarginine and endothelial dysfunction in patients with rheumatoid arthritis. Eur J Rheumatol 3:106–108. https://doi.org/10.5152/eurjrheum.2016.15096
Skeoch S, Bruce IN (2015) Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 11:390–400. https://doi.org/10.1038/nrrheum.2015.40
Spasovski D et al (2013) Determination of the diagnostic values of asymmetric dimethylarginine as an indicator for evaluation of the endothelial dysfunction in patients with rheumatoid arthritis. Arthritis 2013:818037. https://doi.org/10.1155/2013/818037
Spinelli FR, Di Franco M, Metere A, Conti F, Iannuccelli C, Agati L, Valesini G (2014) Decrease of asymmetric dimethyl arginine after anti-TNF therapy in patients with rheumatoid arthritis. Drug Dev Res 75(Suppl 1):S67–S69. https://doi.org/10.1002/ddr.21200
Surdacki A et al (2007) Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 56:809–819. https://doi.org/10.1002/art.22424
Tan X et al (2017) The asymmetric dimethylarginine-mediated inhibition of nitric oxide in the rostral ventrolateral medulla contributes to regulation of blood pressure in hypertensive rats Nitric oxide. Biol Chem 67:58–67. https://doi.org/10.1016/j.niox.2017.04.002
Thum T et al (2005) Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 46:1693–1701. https://doi.org/10.1016/j.jacc.2005.04.066
Turiel M et al (2009) Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology 48:834–839. https://doi.org/10.1093/rheumatology/kep082
Turiel M et al (2010) Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. Cardiovasc Ther 28:e53–e64. https://doi.org/10.1111/j.1755-5922.2009.00119.x
Vatansev H, Ozturk B, Yilmaz S, Sivrikaya A, Dagli M, Kiyici A, Unlu A (2013) Asymmetric dimethylarginine and arginine levels in patients with rheumatoid arthritis Turkish. J Biochem 38:169–175. https://doi.org/10.5505/tjb.2013.51523
Wolf A et al (1997) Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 29:479–485
Funding
This work was supported by Grants from the National Natural Science Foundation of China (81573222).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Handling Editor: J. D. Wade.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhao, CN., Wu, Q., Mao, YM. et al. Elevated circulating asymmetric dimethylarginine levels in rheumatoid arthritis: a systematic review and meta-analysis. Amino Acids 51, 773–782 (2019). https://doi.org/10.1007/s00726-019-02714-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-019-02714-5